The continuing importance of prior stroke in STEMI patients

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 931-936

  Sloan, Michael A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY SURGERY; COST; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EDITORIAL; EMBOLISM; FIBRINOLYSIS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART INFARCTION; HEART RATE; HEMATOMA; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROBABILITY; ST SEGMENT ELEVATION; STRATIFICATION; STROKE; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; HUMANS; INTRACRANIAL EMBOLISM; INTRACRANIAL HEMORRHAGES; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 10644289285     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.010     Document Type: Editorial

References (60)

1. Sloan M.A., Gore J.M. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol. 69:1992;21A-38A
2. Sloan M.A. Neurologic complications of thrombolytic therapy. Biller J. Iatrogenic Neurology. 1997;335-378 Butterworth Heinemann, Boston
3. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 343:1994;311-322
4. ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. ii:1988;349-360
5. Gore J.M., Sloan M., Price T.R., et al. TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study: Thrombolysis in Myocardial Infarction, Phase II, Pilot and Clinical Trial. Circulation. 83:1991;448-459
6. Sloan M.A., Price T.R., Terrin M.L., et al. TIMI Investigators. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II Pilot and Randomized Trial combined experience. Stroke. 28:1997;1107-1114
7. Gore J.M., Granger C.B., Simoons M.L., et al. GUSTO-I Investigators. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial. Circulation. 92:1995;2811-2818
8. Maggioni A.P., Franzosi M.G., Farnia M.L., et al. GISSI Group. Cerebrovascular events after myocardial infarction: Analysis of the GISSI trial. Br Med J. 302:1991;1428-1431
9. Tanne D., Goldbourt U., Zion M., et al. SPRINT Study Group. Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. Stroke. 24:1993;1490-1495
10. Bodenheimer M.M., Sauer D., Shareif B., et al. Relation between myocardial infarction location and stroke. J Am Coll Cardiol. 24:1994;61-66
11. Mahaffey K.W., Granger C.B., Sloan M.A., et al. GUSTO-I Investigators. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I. Circulation. 97:1998;757-764
12. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. i:1986;397-402
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomized trial alteplase versus streptokinase, and heparin versus no heparin among 12,490 patients with myocardial infarction. Lancet. 336:1990;65-71
14. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized alteplase and streptokinase with or without heparin. Lancet. 336:1990;71-75
15. de Jaegere P.P., Arnold A.A., Balk A.H., Simoons M.L. Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors. J Am Coll Cardiol. 19:1992;289-294
16. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarctions. Lancet. 339:1992;753-770
17. EMERAS (Estudio Multricentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 342:1993;767-772
18. The Global Use of Strategies to Open Occluded Coronaries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1994;1631-1637
19. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet. 346:1995;329-336
20. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet. 358:2001;1855-1863
21. Wilcox R.G., Olsson C.G., Skene A.M., et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. ii:1988;525-530
22. O'Connor C.M., Califf R.M., Massey E.W., et al. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long term outcome. J Am Coll Cardiol. 16:1990;533-540
23. Kase C.S., Pessin M.S., Zivin J.A., et al. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am J Med. 92:1992;384-392
24. Longstreth W.T., Litwin P.E., Weaver W.D. MITI Project Group. Myocardial infarction, thrombolytic therapy, and stroke: A community study. Stroke. 24:1993;587-590
25. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 342:1993;759-766
26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123
27. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med. 337:1997;1124-1130
28. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet. 354:1999;716-722
29. The InTIME-II Investigators. Intravenous NPA for the treatment of infracting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J. 21:2000;2005-2013
30. The assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 358:2001;605-613
31. The GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIB/IIIa inhibition: The GUSTO-V randomized trial. Lancet. 357:2001;1905-1914
32. Gurwitz J.H., Gore J.M., Goldberg R.J., et al. Participants in the National Registry of Myocardial Infarction 2. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 129:1998;597-604
33. Brass L.M., Lichtman J.H., Wang Y., et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project. Stroke. 31:2000;1802-1811
34. Mehta S.R., Eikelboom J.W., Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis. Lancet. 356:2000;449-454
35. Llevadot J., Giugliano R.P., Antman E.M. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 286:2001;442-449
36. Granger C.B., Hirsh J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute thrombolytic therapy: Results from the GUSTO-I trial. Circulation. 93:1996;870-878
37. Giugliano R.P., McCabe C.H., Antman E.M., et al. Lower dose heparin is associated with lower rates of intracranial hemorrhage. Am Heart J. 141:2001;742-750
38. Loh E., St. John Sutton M., Wuh C.C.-C., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 336:1997;251-257
39. Simoons M.L., Maggioni A.P., Knatterud G., et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet. 342:1993;1523-1528
40. Selker H.P., Beshansky J.R., Schmid C.H., et al. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI). Circulation. 90:1994;1657-1661
41. Sloan M.A., Giugliano R.P., Thompson S.L., et al. Prediction of intracranial hemorrhage in the InTIME-II trial. J Am Coll Cardiol. 37:(Suppl. A):2001;372A
42. Kandzari D.E., Granger C.B., Simoons M.L., et al. GUSTO-1 Investigators. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-1 Trial). Am J Cardiol. 93:2004;458-461
43. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet. i:1988;545-549
44. Tung C.Y., Granger C.B., Sloan M.A., et al. GUSTO-I Investigators. Effects of stroke on medical resource use and costs in acute myocardial infarction. Circulation. 99:1999;370-376
45. Tanne D., Gottlieb S., Hod H., et al. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) and Israeli Thrombolytic Survey Groups. Incidence and mortality from early stroke associated with acute myocardial infarction in the prethrombolytic and thrombolytic eras. J Am Coll Cardiol. 30:1997;1484-1490
46. Tanne D., Yaari S., Goldbourt U. Risk profile and prediction of long-term ischemic stroke mortality: A 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation. 98:1998;1365-1371
47. Tanne D., Gottlieb S., Caspi A., et al. Israeli Thrombolytic National Survey Group. Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era. Arch Intern Med. 158:1998;601-606
48. Reicher-Reiss H., Jonas M., Tanne D., et al. Benzafibrate Infarction Prevention (BIP) Study Group. Prognostic significance of cerebrovascular disease in 11,526 chronic coronary artery disease patients. Am J Cardiol. 82:1998;1532-1535
49. Cotter G., Cannon C.P., McCabe C.H., et al. OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcomes in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. An Heart J. 145:2003;622-627
50. Ryan T.J., Anderson J.L., Antman E.M., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 28:1996;1328-1428
51. Wallentin L., Armstrong P., Granger C., van de Werf F. ASSENT-III PLUS Investigators. Assessment of the safety and efficacy of a new thrombolytic regimen in the pre-hospital setting (ASSENT-III PLUS). Circulation. 106:(23):2002;2986a
52. Wienbergen H., Schiele R., Gitt A.K., et al. MIR and MITRA Study Groups. Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. Am J Cardiol. 87:2001;782-785
53. Weaver W.D., Simes R.J., Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA. 278:1997;2093-2098
54. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet. 361:2003;13-20
55. Cooper HA, Domanski MJ, Rosenberg Y, et al. and the MAGIC Trial Investigators: Acute ST-segment elevation myocardial infarction and prior stroke - An analysis from the Magnesium in Coronaries (MAGIC) trial. Am Heart J 2004;xx:yyy-yyy
56. Morrow D.A., Antman E.A., Charlesworth A., et al. TIMI Risk Score for ST-elevation myocardial infarction: A convenient, bedside clinical score for risk assessment at presentation. An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy. Cir-culation. 102:2000;2031-2037
57. Morrow D.A., Antman E.A., Parsons L., et al. Application of the TIMI Risk Score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 286:2001;1356-1359
58. The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Investigators. Effects of long-term moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 37:2001;475-484
59. van Es R.F., Jonker J.J.C., Verheught F.W.A., et al. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet. 360:2002;109-113
60. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. New Engl J Med. 347:2002;969-974